Protheragen
Obesity



Cediranib maleate

Cat. No.:	OB0225WX-2617
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	10 mg; 25 mg; 50 mg; 100 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	Cediranib maleate is the maleate salt of a high-potency pan-VEGFR inhibitor, exh ibiting IC50 values of less than 1 nM against VEGFR and sub-5 nM against Flt1/4.
Synonym	AZD-2171 maleate; 857036-77-2; Cediranib (maleate); AZD-2171 maleate; Cediranib maleat; (*Z*)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]- 6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline; 4-((4-fluoro-2-methyl-1h-indo l-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline maleate; Quinazo line, 4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(1-pyrrolidinyl)pr opoxy)-, (2*Z*)-2-butenedioate (1:1); 4-((4-Fluoro-2-methyl-1H-indol-5-yl)o xy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline (2*Z*)-but-2-enedio ate; 4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylprop oxy)quinazoline maleate
CAS No.	857036-77-2
Compound CID	11226834
Formula	$C_{25}H_{27}FN_4O_3 \cdot C_4H_{4O_4}$
Formula Weight	566.58

Specification

IUPAC Name	(*Z*)-But-2-enedioic acid;4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6 -methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com
© Protheragen. All rights reserved.

Protheragen Obesity



InChI	InChI=1S/C25H27FN4O3.C4H4O4/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30;5-3(6)1-2-4(7)8/h6-7,12-15,29H,3-5,8-11H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1-
InChI Key	JRMGHBVACUJCRP-BTJKTKAUSA-N
SMILES string	CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5.C(=C\C(=O)O)\C(=O)O
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Cediranib maleate is employed in oncology research as a potent pan-VEGFR inhibit or to investigate the disruption of tumor vascularization and the inhibition of growth factor-mediated signaling.

Library Information

Target	VEGFR
Receptor	VEGFR
Pathways	Protein tyrosine kinase
Plate Number	L6700-06
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	100 mg/mL; 176.5 mM
ALogP	1.765
HBA_Count	7
HBD_Count	1
Rotatable Bond	10

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com
© Protheragen. All rights reserved.